Onkologie. 2011:5(4):215-218

Treatment of colorectal cancer in 2011

Tomáš Büchler
Onkologické oddělení Fakultní Thomayerovy nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha

Complete surgical removal of the primary tumour and regional lymph nodes is the most important step in curative treatment of nonmetastatic

colorectal cancer. Adjuvant chemotherapy significantly increases the proportion of patients surviving long-term without

evidence of disease. Chemotherapy and targeted therapy have become the mainstay of metastatic colorectal cancer treatment. It is

critical to identify those patients with metastatic disease who could benefit from metastasectomy.

Keywords: colon cancer, rectal cancer, chemotherapy, targeted therapy

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Büchler T. Treatment of colorectal cancer in 2011. Onkologie. 2011;5(4):215-218.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Gelnarová E, et al. Cancer incidence and mortality in the Czech Republic. Klin Onkol 2010; 23: 311-324. Go to PubMed...
    2. Alberts SR, Goldberg RM. Gastrointestinal tract cancers. In: Casciato DA, Territo MC (eds). Manual of Clinical Oncology. Lippincott Williams and Wilkins, Philadelphia, 2009: 188-236.
    3. Česká onkologická společnost ČLS JEP. Zásady cytostatické léčby maligních onkologických onemocnění. 13. vydání. 1. 8. 2011.
    4. NCCN Clinical Practice Guidelines in Oncology. Colon cancer Version 3.2011. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf [přístup 26.6.2011].
    5. Labianca R, Nordlinger B, Beretta GD, et al. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): 70-7. Go to original source... Go to PubMed...
    6. Van Cutsem E, Nordlinger B, Cervantes A, et al. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010; 21(Suppl 5): 93-97. Go to original source... Go to PubMed...
    7. Glimelius B, P?hlman L, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): 82-6. Go to original source... Go to PubMed...
    8. Anderson JH, Hole D, McArdle CS. Elective versus emergency surgery for patients with colorectal cancer. Br J Surg 1992; 79(7): 706-709. Go to original source... Go to PubMed...
    9. Chau I, Cunningham D. Adjuvant therapy in colon cancer-what, when and how? Ann Oncol 2006; 17: 1347-1159. Go to original source... Go to PubMed...
    10. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370(9604): 2020-2029. Go to original source... Go to PubMed...
    11. IMPACT Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT). Lancet 1995; 345: 939-44. Go to original source...
    12. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007 Jun; 25(16): 2198-2204. Go to original source... Go to PubMed...
    13. Haller DG, Cassidy J, Tabernero J. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (DFS). 2010 Gastrointestinal Cancers Symposium, Abstract No: 284, http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2193 (přístup 9.6.2010).
    14. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25(1): 102-109. Go to original source... Go to PubMed...
    15. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704. Go to original source... Go to PubMed...
    16. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19(10): 1720-1726. Go to original source... Go to PubMed...
    17. Bonnetain F, Bosset J, Gerard J, et al. An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? J Clin Oncol 29; 2011; (Suppl): 3506. Go to original source...
    18. De Paoli A, Chiara S, Luppi G, et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 2006; 17: 246-251. Go to original source... Go to PubMed...
    19. Krishnan S, Janjan NA, Skibber JM, et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2006; 66: 762-771. Go to original source... Go to PubMed...
    20. Slampa P, Kocáková I, Sefr R, et al. Neoadjuvant treatment for locally advanced rectal adenocarcinoma with concomitant radiotherapy and oral capecitabine. J BUON 2004; 9: 33-40. Go to PubMed...
    21. Soumarova R, Skrovina M, Bartos J, et al. Neoadjuvant chemoradiotherapy with capecitabine followed by laparoscopic resection in locally advanced tumors of middle and low rectum - toxicity and complications of the treatment. Eur J Surg Oncol 2010; 36: 251-256. Go to original source... Go to PubMed...
    22. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 200; 360(14): 1408-1417. Go to original source... Go to PubMed...
    23. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011; 377(9783): 2103-2114. Go to original source... Go to PubMed...
    24. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28(31): 4697-4705. Go to original source... Go to PubMed...
    25. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as secondline treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-4713. Go to original source... Go to PubMed...
    26. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572. Go to original source... Go to PubMed...
    27. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27(5): 672-680. Go to original source... Go to PubMed...
    28. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006; 24: 394-400. Go to original source... Go to PubMed...
    29. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27(34): 5727-5733. Go to original source... Go to PubMed...
    30. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leukovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90: 1190-1197. Go to original source... Go to PubMed...
    31. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237. Go to original source... Go to PubMed...
    32. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25(12): 1539-1544. Go to original source... Go to PubMed...
    33. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotekan in irinotekan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345. Go to original source... Go to PubMed...
    34. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664. Go to original source... Go to PubMed...
    35. Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005; 16: 425-429. Go to original source... Go to PubMed...
    36. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leukovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23: 9243-9249. Go to original source... Go to PubMed...
    37. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835. Go to original source... Go to PubMed...
    38. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11(1): 38-47. Go to original source... Go to PubMed...
    39. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664. Go to original source... Go to PubMed...
    40. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. Go to original source... Go to PubMed...
    41. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019. Go to original source... Go to PubMed...
    42. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671. Go to original source... Go to PubMed...
    43. Hoff P, Hochhaus A, Pestalozzi B, et al. Cediranib + FOLFOX/XELOX versus placebo + FOLFOX/XELOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase 3 study. Program and abstracts of the 35th European Society of Medical Oncology Congress; October 8-12, 2010; Milan, Italy. Abstract LBA19.
    44. Tveit K, Guren T, Glimelius B, et al. Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. J Clin Oncol 2011; 29(Suppl 4): 365. Go to original source...
    45. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.